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1. Introduction 
Hypertension control is unsatisfactory in most countries and it carries an unacceptably high 
cardiovascular risk and death toll (Mancia et al., 2007) The reasons for the poor blood 
pressure control are different and interrelated (motivation of patients and physicians, costs, 
compliance, access to health care, secondary and resistant hypertension). Among them, 
resistant hypertension is receiving considerable attention, as it may be caused by 
unrecognized secondary hypertension, mainly primary aldosteronism (PA).  
We have recently shown in patients with resistant hypertension elevated aldosterone / renin 
ratio (ARR) and reduced RGS2 expression. We, therefore, hypothesize that in many patients 
resistant hypertension is secondary to disproportionate aldosterone secretion caused by 
blunted inhibition of angiotensin II (Ang II) cellular effects due to low RGS2 expression. 
2. Resistant or uncontrolled hypertension 
Resistant hypertension is defined as blood pressure remaining above the goal levels in spite of 
the concurrent use of three antihypertensive agents of different classes at the same time, with 
diuretic as one of the three agents and all agents prescribed at optimal dose (Calhoun et al., 
2008). This implies that also patients whose blood pressure needs four or more drugs to be 
controlled should be considered resistant to treatment. Resistant hypertension identifies 
patients who are at a high risk of having secondary and reversible causes of hypertension or 
patients who may benefit from further diagnostic and therapeutic work up. Uncontrolled 
hypertension is not synonymous of resistant hypertension as uncontrolled hypertension 
includes patients who do not reach blood pressure control due to poor adherence or an 
inadequate treatment regimen, as well as patients with true treatment resistance. 
2.1 Prevalence 
The prevalence of resistant hypertension is unknown, even if according to the literature it is 
not an uncommon condition: the majority of studies indicate that less than 40% of elderly 
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patients reach a goal blood pressure with drugs. Among high risk populations and, in 
particular with application of the lowest blood pressures goal recommendation of the 
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure (JNC 7) for patients with diabetes mellitus or chronic 
kidney disease, the percentage of uncontrolled hypertensive patients is even higher. 
2.2 Prognosis 
Prognosis of patients with resistant hypertension compared with patients with drug 
controlled hypertension is likely to be worse due to the long history of poorly controlled or 
uncontrolled hypertension and the presence of commonly associated cardiovascular risk 
factors, such as obstructive sleep apnea, diabetes, left ventricular hypertrophy and chronic 
kidney disease. Yet, no clinical trial has been conducted to specifically evaluate its 
associated increased risk.  
The cardiovascular risk reduction associated to the treatment of resistant hypertension is 
unknown. The benefits of effective treatment, however, are supposed to be substantial, as 
suggested by several outcome studies, and, therefore, achievement of goal pressure levels 
should always be urged.  
2.3 Patient characteristics 
Populations who are at the highest risk of developing resistant hypertension have been 
investigated. The strongest predictors of treatment resistance are chronic kidney diseases, 
obesity and diabetes mellitus. Differences between races and genders have been reported, 
since blacks and women are at higher risk of resistant hypertension. 
Blood pressure is considered uncontrolled most often because of persistent elevation of 
systolic values as patients treated with antihypertensive drugs reach correct diastolic more 
easily than systolic values. This diversity in systolic versus diastolic blood pressure control 
worsens with increasing age of patients, as arterial stiffness (strongly related with age) is the 
main cause of isolated systolic hypertension. This explains why the strongest predictor of 
the lack of blood pressure control is old age. High baseline systolic pressure was associated 
with increased risk of never reaching goal blood pressure (Lloyd-Jones et al., 2002). Other 
strong predictors of poor systolic blood pressure control are the presence of left ventricular 
hypertrophy and obesity (that is, body mass index [BMI] greater than 30 kg/m2). The 
prevalence of resistant hypertension is predicted to increase in older and heavier cohorts in 
association with the growing prevalence of diabetes and chronic kidney disease. 
In terms of poor diastolic pressure control, the strongest negative predictor is obesity, with 
goal blood pressure reached one third less often in obese than in lean patients. 
2.4 Genetics / pharmacogenetics 
The genetics of hypertension is complex and there is no known single gene playing a major 
role, but rather many different genes contributing all together with different environmental 
factors in rising blood pressure. Due to its particular type, it is reasonable that in resistant 
hypertension genetic factors may play an even greater role than in the general hypertensive 
population. However, in resistant hypertensive population, genetic studies are limited and 
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based on a very small number of patients, even if identification of genetic influences on 
resistance to current therapies might lead to development of new therapeutic targets. Gene 
variants of ENaC (epithelium sodium channel) (Hannila-Handelberg et al., 2005) and of 
CYP3A5 enzyme (11-hydroxysteroid dehydrogenase type 2) (Givens et al., 2003; Ho et al., 
2005) have been demonstrated, focusing attention on sodium homeostasis, and on cortisol 
and corticosterone metabolism but the clinical relevance of these mutations is unclear. 
2.5 Pseudoresistance 
Pseudoresistance is the condition of poor blood pressure control with no real treatment 
resistance and no coexisting factors causing persistently high blood pressure values. There 
are many causes of pseudoresistance that can be related either to medical or to lifestyle 
factors. These conditions should be kept in mind and carefully searched in resistant 
hypertensive patients to avoid incorrect classification of hypertension. 
Among the medical related causes of pseudoresistant hypertension, the most frequent are 
poor blood pressure measurement techniques, poor adherence to therapy, white-coat effect 
and drug-related causes. 
Poor blood pressure technique consists in inaccurate measurement of blood pressure, 
resulting falsely high. Blood pressure should be measured only after the patient has been 
sitting quietly for a few minutes and with the use of adequate size cuff, not too small as it 
often happens. (Pickering et al., 2005) Poor adherence to therapy is probably the main cause 
of the lack of blood pressure control (Yiannakopoulou et al., 2005): near 40% of newly 
diagnosed hypertensive patient discontinue therapy during the first year of drug treatment 
(Caro et al., 1999; Mazzaglia et al., 2005) and 60 % of patients at five and ten year follow up 
show poor adherence to the suggested treatment (Van Wijk et al., 2005) . It should be 
noticed that the percentage of poor adherence to therapy falls from 40 to 15 % when the 
patients are seen in hypertension specialist clinic rather then at primary care.  
White-coat effect consists in clinic blood pressure values persistently elevated while out-of-
office values are normal or significantly lower (Brown et al., 2005) . The prevalence of this 
condition is similar in patients with resistant hypertension and in the general hypertensive 
population, with values in the range of 20% to 30%. It can be identified with ambulatory 
blood pressure recording showing normal out of office blood pressure values (Redon et al., 
1998; Muxfeldt et al, 2003; Pierdomenico et al., 2005). 
Drug-related causes are due either to incorrect antihypertensive drug assumption or to drug 
interactions. Identification of poor adherence is clinically relevant to stop useless continuous 
modification of the treatment regimens and further investigations. Drug interactions should 
always be looked for, in particular in those patients assuming complex combination 
therapies. Several classes of drugs can increase blood pressure and contribute to treatment 
resistance: 
 stimulants (dextroamphetamine, amphetamine, methamphetamine, methylphenidate, 
dexmethylphenidate) ; 
 sympathomimetic agents (like nasal decongestants, diet pills and cocaine); 
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 glucocorticoids (such as prednisone); 
 corticosteroids (mainly the ones with the greatest mineralcorticoid effect such as 
cortisone and hydrocortisone); 
 oral contraceptives; 
 cyclosporine and calcineurine inhibitors; 
 erythropoietin; 
 Natural products such as licorice (common in oral tobacco products) or herbal 
compounds (ephedra or ma huang). 
The effect of these agents is highly variable with most patients manifesting little or no effect 
and other individuals showing severe blood pressure elevations (Radack et al., 1987; Conlin 
et al., 2000). Due to large use and wide distribution, non narcotic analgesics are probably the 
most common interacting medicaments with antihypertensive drugs (Dedier et al, 2005; 
Forman et al., 2005). NSAIDs induced blood pressure increase is modest but predictable, 
apart from patients with significant fluid retention and/or acute kidney disease in which 
there is subsequent sodium and fluid retention and rebound pressure relevant increase due 
to inhibition of renal prostaglandin production. 
Among lifestyle factors the most relevant are obesity, excessive dietary salt and alcohol 
intake. Obesity is associated with the need for an increased number of antihypertensive 
medications, a more severe hypertension and increased probability of difficult achieving or 
never achieving appropriate blood pressure control (Bramlage et al., 2004). Mechanisms of 
obesity-induced hypertension are multiple, complex and not fully understood: activation of 
the renin-angiotensin-aldosterone system, impaired sodium excretion and increased 
sympathetic nervous system activity (Hall et al., 2003). As a consequence, obesity is a 
common feature of patients with resistant hypertension (Nishizaka et al., 2005).  
Excessive dietary salt intake sustains resistant hypertension both by increasing blood 
pressure directly and by decreasing the effect of most classes of antihypertensive agents 
(Weinberger 1988; He & MacGregor, 2004; Luft & Weinberger, 1988;). These effects are 
mainly found in salt-sensitive patients, like the elderly, those suffering from chronic kidney 
disease (Boudville et al, 2005) and both African and American races. 
Alcohol intake at high doses is associated with increased risk of hypertension and resistant 
hypertension. Epidemiological studies have shown a direct relationship between alcohol 
intake and blood pressure, which is particularly evident when 28 g of ethanol per day are 
exceeded (Henningsen et al., 1980; Aguilera et al., 1999; Wildman et al., 2005). All the 
subpopulations that have been analyzed (males, females, Caucasian and African race) show 
a blood pressure increase related to alcohol consumption, but the African race shows a 
blood pressure greater raise compared to Caucasians at the same intake. Chronic daily 
intake of alcohol it is not required for the hypertensive effect, since it has been proven that 
also consumption confined to only a few days a week is associated with increased blood 
pressure. Prospective studies have demonstrated that cessation of heavy alcohol ingestion 
reduced 24-hour ambulatory systolic blood pressure. 
2.6 Secondary causes 
Secondary causes of hypertension are common among patients with resistant hypertension, 
mainly in older patients due to high incidence of sleep apnea syndrome, renal parenchymal 
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disease, diabetes mellitus, renal artery stenosis and primary aldosteronism. Uncommon 
causes of secondary resistant hypertension include pheochromocytoma, Cushing’s 
syndrome, hyperparathyroidism, aortic coarctation. 
2.6.1 Obstructive sleep apnea 
Obstructive sleep apnea is strongly associated with hypertension. In normotensive subjects 
it predicts development of hypertension, and it is very common in patients with resistant 
hypertension (Nieto et al., 2000; Peppard et al., 2000). There is a significant gender 
distribution, with males more affected than females. The more severe and untreated is sleep 
apnea syndrome, the less likely is blood pressure controlled despite the use of 
polymedications (Grote et al., 2000; Lavie & Hoffstein, 2001) Sleep apnea seems to create and 
maintain hypertension by increasing sympathetic nervous system (SNS) activity generated 
by intermittent hypoxemia; the SNS hyperactivation increases cardiac output, peripheral 
vascular resistances and fluid retention (Grassi et al., 2005). 
2.6.2 Renal parenchymal disease 
Renal parenchymal disease is both cause and complication of uncontrolled hypertension. 
Serum creatinine higher than of 1.5 mg/dL is a strong predictor of failure to achieve blood 
pressure goal, due to increased sodium and water retention and intravascular volume 
expansion (Klahr et al., 1994; Buckalew et al., 1996). 
2.6.3 Diabetes 
Diabetes and hypertension are commonly associated, in particular in patients with resistant 
hypertension. Diabetes associated insulin resistance is supposed to contribute to the 
development of hypertension directly through sympathetic nervous activity, vascular 
smooth muscle cell proliferation, and increased sodium retention with intravascular volume 
expansion (Bakris, 2001) . 
2.6.4 Renovascular disease 
Renal artery stenosis is a common finding in resistant hypertension, with several studies 
suggesting a percentage of renovascular disease in resistant hypertension between 12 and 
15%. More than 90% of renal artery stenoses have an atherosclerotic origin, with increased 
incidence in smokers, older patients, and widespread atherosclerotic disease (Aqel et al., 
2003; Cuckson et al., 2004). Less than 10% of renal lesions are fibromuscular in etiology, 
developing particularly in young women. Specific diagnostic studies should be performed 
when renovascular disease is suspected, such as ultrasound, magnetic resonance 
angiography (MRA), renal scintigraphy, and computed tomography angiography (Leiner et 
al., 2005). 
2.6.5 Pheochromocytoma 
Pheochromocytoma accounts for a small number of secondary causes of resistant 
hypertension. Its prevalence is 0.1% to 0.6% among hypertensive patients, and even if the 
prevalence as a cause of resistant hypertension is unknown, it has to be underlined that 95% 
of pheochromocytomas show hypertension at clinical onset and 50% have resistant 
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hypertension (Omura et al., 2004; Sinclair et al., 1987). It should be suspected in every 
hypertensive patient with headaches, palpitations, and sweating, typically occurring in an 
episodic way; not all pheochromocytomas show up with these typical symptoms, and this is 
the reason why there is often a delay between the initial symptoms and the final diagnosis, 
with an average delay of three years. Moreover, pheochromocytoma is characterized by 
increased blood pressure variability due to inconstant catecholamine release, which 
represents an additional independent risk factor beyond increased blood pressure itself for 
cardiovascular morbidity and mortality (Kikuya et al., 2000; Björklund et al., 2004; Zelinka et 
al., 2005). 
2.6.6 Cushing’s syndrome 
The mechanism that causes hypertension in Cushing’s syndrome is overstimulation of the 
nonselective mineralocorticoid receptor by cortisol (Moneva & Gomez-Sanchez, 2002; 
Ferrari, 2003) , even if other factors contribute to hypertension in this disease, such as sleep 
apnea and insulin resistance (McFarlane et al, 2001) .  
Cortisol is the hormone which is mainly increased in Cushing syndrome and hypertension 
is present in 70-85% of patients suffering from this syndrome. Hypertension is often 
resistant because of the cortisol dependent pressor activity: the most common therapeutic 
agents (renin-angiotensin system blockers, calcium channel antagonists, adrenergic blockers, 
and diuretics) are frequently ineffective. The most effective antihypertensive agents are 
mineralocorticoid receptor antagonists (such as spironolactone or eplerenone), but 
frequently only surgical removal of an adrenocorticotropic hormone (ACTH) or another 
cortisol-producing tumor allows effective blood pressure control. Target organ damage and 
overall cardiovascular risk in Cushing’s syndrome is more severe than in primary 
hypertension, because the disease is associated with other cardiovascular risk factors such as 
metabolic syndrome, diabetes mellitus, obesity, sleep apnea syndrome, and dyslipidemia 
(Sacerdote et al., 2005).  
3. Primary aldosteronism and resistant hypertension 
Primary aldosteronism (PA) is a clinical condition sustained by overproduction of the 
mineralocorticoid hormone aldosterone by the adrenal glands. The overproduction is 
relatively independent by the renin-angiotensin system (RAS) activity, and non 
suppressible by sodium loading. PA was considered to be a rare cause of secondary 
hypertension until recently. Early epidemiologic studies have claimed the prevalence of 
PA to be less than 1% of hypertensive patients. On the contrary, there is evidence from 
several recent studies that PA is a much more common cause of resistant hypertension 
than had been suspected before, and particularly common in patients with resistant 
hypertension, its prevalence being between 10 and 15% among patients with severe 
hypertension (Gordon et al., 1994; Fardella et al., 2000; Mosso et al., 2003). Several authors 
have suggested a direct role of aldosterone autonomy as a mechanism for drug resistance 
and have recommended the search for primary aldosteronism in cases of severe or drug 
resistant hypertension as primary aldosteronism was found in 20% of patients with 
resistant hypertension. Primary aldosteronism is, therefore, the most common cause of 
secondary hypertension. 
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Bilateral idiopathic hyperaldosteronism (IHA) and aldosterone-producing adenoma (APA) 
are the most common subtypes of primary aldosteronism. A rarer cause of primary 
aldosteronism, unilateral hyperplasia or primary adrenal hyperplasia, is generated in a 
single adrenal gland by hyperplasia of the zona glomerulosa. Two forms of familial 
hyperaldosteronism (FH) have been described: FH type I and FH type II. FH type I, or 
glucocorticoid-remediable aldosteronism, is autosomal dominant in inheritance and 
associated with variable degrees of hyperaldosteronism, high levels of hybrid steroids (e.g. 
18-hydroxycortisol and 18-oxocortisol), ameliorated by exogenous glucocorticoids. FH type 
II refers to the familial occurrence of APA or IHA, or both (Young, 2003) . 
A number of studies demonstrate that primary aldosteronism is strongly associated with 
target organ damage and elevated rate of cardiovascular events. Indeed, 
hyperaldosteronism produces oxidative stress with oxidative damage to DNA, 
inflammation, and nongenomic effects (with cardiovascular remodeling, hypertrophy, 
fibrosis, endothelial dysfunction and increased arterial stiffness). This reflects in increased 
cardiovascular events, such as impaired systolic and diastolic ventricular function, atrial 
fibrillation, microalbuminuria, increased incidence of ischemic and hemorrhagic stroke, 
pulmonary edema and myocardial infarction. (Takeda et al., 1995; Rocha et al., 2002; 
Farquharson & Struthers, 2002; Sechi et al., 2006; Rossi et al., 2008; Schupp et al., 2010).  
3.1 Diagnosis 
Diagnosis of PA is made by a three step approach: screening; confirmation / exclusion; 
subtype diagnosis. Serum potassium level cannot be used as an indicator of the presence of 
hidden primary aldosteronism due to high prevalence of normokalemic PA, and the 
prevalence of hypokalemia increasing with severity of hypertensive disease. These data 
suggest that hypokalemia is a late manifestation of the disorder following the onset of 
hypertension. 
3.1.1 Screening test 
Resistant hypertension is enlisted among the subtypes of hypertension which should 
undergo a screening test for primary aldosteronism (Funder et al, 2008) . 
There is general consensus that ARR is the most reliable available mean for primary 
aldosteronism screening, a validated and assured index of inappropriate aldosterone 
activity, and a valid screening assay even without discontinuation of antihypertensive 
medications (Gallay et al., 2001). ARR provides the best parting of patients with primary 
aldosteronism from essential hypertensive subjects. However, there is no agreement on the 
ARR cut-off value and on whether the absolute aldosterone level should also be taken into 
account. It should be noted that the optimal ARR cut-off value (as well as the aldosterone 
level after confirmatory test) is dependent on the assay used to measure aldosterone. 
Different assays, although demonstrating good overall correlation with one another, often 
show significant differences in absolute aldosterone concentrations (Pizzolo et al., 2006). In 
order to compare results from different studies and to use the same cut-offs for screening 
and confirmation, aldosterone assays thus need to be standardized. Moreover, ARR is 
strongly dependent on plasma renin activity (PRA), so that anyone with suppressed PRA 
will have increased ARR: this implies that ARR needs to be interpreted in light of 
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aldosterone plasma level (>15 nd/dL) and the lowest detectable level of PRA. Another 
debated issue is the use of direct active renin assay instead of PRA. PRA and direct renin are 
closely and strongly correlated, but the correlation is weaker for the low range of values 
compared with the high/normal range of values (Hartman et al., 2004) .  
3.1.2 Confirmatory testing 
Because of the high prevalence of low renin hypertension, it is important to stress that 
increased ARR is not diagnostic of PA by itself, and a confirmatory test is most often 
required. This is to avoid a large number of hypertensive patients inappropriately 
undergoing costly and potentially harmful procedures. The choice of the test remains a 
matter of debate and there is currently insufficient direct evidence to recommend one in 
particular. The most widely used and approved by the guidelines tests are: fludrocortisone 
suppression test (FST), intravenous saline load test (SLT), oral sodium loading test (OLT) 
and captopril challenge (CC). FST, SLT and OLT include the administration of salt and thus 
should be considered preferable to CC for confirming PA (Mulatero et al., 2010). CC has the 
advantage of being relatively cheap, safe, well tolerated and easy to perform. Because of the 
high rate of false positive diagnoses to which it is related, it should only be used in patients 
at risk of volume expansion.  
3.1.3 Subtype differentiation 
All patients affected by PA should undergo an adrenal HTCT scan as the initial study for 
subtype differentiation in order to rule out an adrenocortical carcinoma. Magnetic resonance 
offers no advantage over CT, and adrenal scintiscan with [6 -131I] iodomethyl-19-
norcholesterol has a low sensitivity and specificity for APA. CT scanning should be 
performed by an expert and motivated radiologist to diminish inadequacy of CT scanning to 
distinguish between APA and IHA because of small size of some adenomas. The Endocrine 
Society Guidelines recommend that all patients for whom the surgical treatment is 
practicable and desired should undergo adrenal venous sampling (AVS) as the gold 
standard to differentiate unilateral from bilateral disease (Young & Stanson, 2009)  
3.1.4 ARR to identify disproportionate aldosterone production 
High aldosterone secretion may play a role in the pathogenesis of increased blood pressure 
in resistant hypertensives even when PA cannot be diagnosed by clinical and instrumental 
criteria. We have shown that a mild elevation of ARR and plasma aldosterone, which are not 
reduced to a significant extent by oral captopril administration during CC, predict poor 
blood pressure response to antihypertensive agents. The clinical features and outcome of 
these patients with high ARR were indistinguishable from those of hypertensive patients 
with clinically diagnosed IHA: both reached blood pressure goal in a smaller fraction and in 
a longer time than patients with ARR in the normal range (Sartori et al., 2006).  The cause(s) 
of the disproportionately high aldosterone levels which are not inhibited to a significant 
extent by the inhibition of Ang II production by captopril remain(s) unknown but they may 
be related to abnormal regulation of aldosterone production by Ang II (see below). ARR 
should be, therefore, performed in all patients with resistant hypertension to demonstrate a 
disproportionate aldosterone secretion and encourage treatment with aldosterone 
antagonists to achieve a more effective blood pressure reduction. 
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3.2 Treatment of primary aldosteronism 
Surgical treatment should be offered to eligible patients with unilateral adrenal disease; it 
consists in unilateral adrenalectomy. It has been shown to improve blood pressure control. 
In patients who are unable or unwilling to undergo surgery, or with a bilateral adrenal 
disease, treatment with a mineralcorticoid receptor antagonist should be started. Treatment 
of aldosterone excess either with spironolactone or with unilateral adrenalectomy was 
found to reduce the high cardiovascular risk of this patient group (Milliez et al., 2005). The 
benefit of controlling PA is also demonstrated after a long period of therapy: treated patients 
with PA had similar rates of cardiovascular events as hypertensive patients without PA after 
a 12-years follow up. The best cardiovascular outcome was seen in younger patients and in 
those with a shorter duration of disease. These results stress the need of early recognition 
and treatment to reverse the adverse effects of aldosterone excess. 
3.2.1 Mineralocorticoid receptor antagonists 
Spironolactone is a direct antagonist of the mineralcorticoid receptor and it is a powerful 
add-on agent to the antihypertensive regimen in patients with resistant hypertension. When 
added to a regimen of three drugs including a diuretic, spironolactone lowers blood 
pressure significantly, with achievement of blood pressure control in a high percentage of 
patients. This effect is similar in patients with or without evidence of aldosterone excess, 
with no gender or ethnic difference. Indeed, similar degrees of blood pressure reduction 
were achieved regardless of baseline plasma aldosterone or PRA values. This underscores 
the contributory role of relative aldosterone excess to treatment resistance, such that even 
those with presumably low levels of aldosterone benefit from mineralcorticoid receptor 
antagonists use. (Nishizaka et al., 2003; Sartori et al., 2006; De Souza et al., 2010) This is in 
contrast with other studies that showed that high ARR predicted the antihypertensive 
efficacy of spironolactone (Eide et al., 2004); these contrasting results may be explained by 
the considerably higher spironolactone dose administered in patients with demonstrated 
PA, generating a strong difference in the two populations. 
The importance of relative aldosterone excess in promoting treatment resistance is 
emphasized also in another recent study: spironolactone was added either to an ACE-I or to 
an ARB theraphy and compared to ACE-I plus ARB combined therapy. Greater blood 
pressure reduction was achieved when spironolactone was added to an ACE inhibitor or an 
ARB versus dual RAS blockade (Alvarez-Alvarez et al., 2010). These results suggest that 
aldosterone excess plays a major role in the pathogenesis of treatment resistance, and that 
hypersecretion of aldosterone is relatively autonomous of the RAS activity, so that the 
amplitude of blood pressure lowering is greater in patients given the mineralcorticoid 
receptor antagonist compared to those on dual blockade. Furthermore, since the study 
excluded patients with PA, the results show that resistant hypertensive patients in general 
have an element of relative aldosterone excess, even if aldosterone falls within the normal 
range. (Acelajado & Calhoun, 2011). 
Mineralcorticoid receptor antagonists are also anti-proteinuric: reduction of albuminuria 
was demonstrated in patients with diabetes or chronic kidney disease, nephropathy, or 
persistent microalbuminuria. In case of chronic kidney disease, spironolactone alone was 
able to reduce proteinuria and slow down renal progression (Bianchi et al., 2006). 
www.intechopen.com
 
Genetics and Pathophysiology of Essential Hypertension 
 
52
Treatment with mineralcorticoid receptor antagonists not only controls blood pressure 
levels and proteinuria, but also reverses or attenuates the cardiovascular injury mediated by 
aldosterone excess. This is particularly true for the nongenomic effects, which lead to tissue 
fibrosis, arterial stiffness, and increased oxidative stress. In patients with resistant 
hypertension spironolactone reduces left ventricular mass index after 3 and 6 months of 
therapy, both in patient with PA and in those with normal renin - angiotensin- aldosterone 
levels (Gaddam et al., 2010) . The extent of regression of the left ventricular mass index 
achieved with spironolactone treatment is greater for patients with PA compared to those 
without. 
If patients with both resistant hypertension and PA are selected, further interesting benefits 
of therapy with spironolactone are shown on nongenomic effects. Spironolactone 
significantly decreases brain natriuretic peptide (BNP), an effect that was not seen in those 
with normal or low aldosterone levels; this indicates a prominent diuretic effect even when 
administered on top of chronic thiazide diuretic treatment. In another study on resistant 
hypertension and PA, flow-mediated dilation of the brachial artery increased with 
spironolactone treatment as an indication of reduced arterial stiffness and improvement of 
endothelial function, and this effect was independent of the change of blood pressure 
(Nishizaka et al., 2004) . 
3.2.2 Adverse effects 
Adverse effects of spironolactone use are breast tenderness, gynecomastia, erectile 
dysfunction, and menstrual irregularities, as a result of the binding of spironolactone to 
androgen receptors, preventing their interaction with dihydrotestosterone. All these major 
adverse effects warrant monitoring (Marrs, 2010). The incidence of these effects is rare (2–
9%) and they are all reversible after discontinuing treatment. If a more selective MR 
antagonist is used (such as eplerenone), no or less antiandrogen effects is shown, given its 
lower affinity for progesterone and androgen receptors. A comparison between 
spironolactone and eplerenone in patients with primary hypertension and bilateral adrenal 
hyperplasia showed that the two agents achieved similar degrees of blood pressure 
lowering in patients with PA (Karagiannis et al., 2008). A direct comparison of these two 
agents in patients with resistant hypertension has not been conducted so far. Furthermore, 
eplerenone has not yet been specifically evaluated for the treatment of resistant 
hypertension and it is not available in several countries. 
Hyperkalemia can also be a side effect of treatment with mineralcorticosteroid antagonists, 
especially when multidrug therapy, including renin – angiotensin system blockers, is 
prescribed or in patients with chronic kidney diseases. This effect can be reversed by 
discontinuing the drug or reducing the dose.  
4. RGS2 
The above mentioned studies, showing benefits of aldosterone antagonists in patients with 
resistant hypertension, strongly support a role of aldosterone excess, beyond true primary 
aldosteronism, as a major cause of treatment resistance. Furthermore, data from our 
laboratory have shown that disproportionately high aldosterone levels associated to poor 
response to inhibition of Ang II production by captopril are prevalent in resistant 
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hypertension (Sartori et al., 2006). Therefore, we have investigated the signal transduction 
pathways of Ang II to clarify whether the inappropriately high aldosterone levels are caused 
by abnormal regulation of aldosterone production by Ang II in the adrenals. 
The pressor effects of Ang II action are mediated by stimulation of G protein-coupled 
receptors (GPCRs), which are mediators of the activity of several other important 
cardiovascular neurotransmitters and hormones, including noradrenaline, adrenaline, 
endothelin, thrombin, vasopressin, acetylcholine, serotonin and sphingosine-1-phosphate 
(S1P). G-proteins are widely expressed throughout the cardiovascular system and thus play 
an important role in the physiological regulation of the cardiovascular system. 
Signaling by hormones and neurotransmitters that activate G protein-coupled receptors 
(GPCRs) maintains blood pressure within the normal range despite large changes of cardiac 
output that can occur within seconds. The blood pressure regulation requires, therefore, 
precise kinetic control of GPCR signaling. Alteration of GPCR signaling is a salient feature 
of hypertension and its associated cardiovascular complications and hypertension is often 
associated with increased activity of GPCR-mediated signaling in the heart and blood 
vessels. Accordingly, these pathways are common targets of inhibitors used to treat 
hypertension and heart disease (angiotensin-converting enzyme -ACE- inhibitors - and Ang 
II receptor antagonists) (Rockman et al., 2002). 
4.1 G-Protein structure and function 
The G-protein heterotrimer is composed of a GDP bound G┙ subunit and a G┚┛ 
heterodimer. Different gene families consisting of 16┙, 6┚ and 12┛ genes encode the three 
subunits that can form heterotrimeric complexes in various combinations. It is the G┙ 
subunit families (Gs, Gq, Gi etc.), however, that define the signaling context of the 
heterotrimer via its ability to couple selectively to a limited number of seven-
transmembrane domain receptors and effectors. In the absence of extracellular ligand 
(inactive state -OFF state-), the G-protein heterotrimer is coupled to the intracellular surface 
of the receptor. Binding of receptor ligand induces the exchange of GTP for GDP on the G┙ 
subunit and the subsequent dissociation of G┙ from the G┚┛ heterodimer. This condition 
marks the activated (active state -ON state-) state and during this time the G┙ and G┚┛ 
subunits are free to engage the appropriate downstream effector pathways (Clapham & 
Neer, 1997; Hamm 1998). Effector signaling is terminated by the G┙-subunit catalyzed 
hydrolysis of GTP and reformation of the quiescent receptor-coupled heterotrimer. Thus G-
proteins act as molecular time switches that control the onset and lifetime of cellular 
responses to extracellular signals. 
4.2 RGS proteins promote rapid termination of G-protein mediated signals 
G-protein signaling pathways are tightly coupled to rapid ON–OFF kinetics of the cell 
physiological effectors, including membrane ion channels. As the intrinsic rate of G┙-
mediated GTP hydrolysis is very slow, GTPase-activating proteins (GAPs) are needed to 
achieve the rapid ON–OFF kinetics of G-protein signaling observed in vivo. Regulators of G 
protein signaling (RGS) proteins contain a 120 amino acid GAP domain (Berman et al., 1996) 
that increase the rate of G┙-mediated GTP hydrolysis by up to 2000 times (Ross & Wilkie, 
2000). Accordingly, RGS proteins attenuate GPCR-mediated signaling by promoting faster 
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signal termination kinetics following removal of a GPCR agonist and decreasing GPCR 
agonist sensitivity (higher agonist concentrations are needed to achieve the same degree of 
signaling). In addition, the RGS protein GAP domain can inhibit signaling by blocking G┙ 
binding to downstream effector molecules (Ceolotto et al., 2001). Three RGS proteins, RGS2, 
RGS4, and RGS5, are among the most highly expressed proteins in the heart and blood 
vessels. The genes encoding these three proteins are located within the region on 
chromosome 1 associated with blood pressure variation. 
4.3 RGS2  
Regulators of G-protein Signaling (RGS) proteins are a large family of important 
endogenous regulators of GPCR signaling: RGS proteins have an established role as 
inhibitors of G-protein signaling in cardiovascular tissues and, therefore, are important 
endogenous regulators of blood pressure. 
4.3.1 RGS2 inhibits Gαq and adenylatecyclase-mediated signaling 
RGS2 is unique owing to its preferential interaction with G┙q/11 (and Gas) and its low 
affinity for G┙i (Heximer et al., 1999; Cladman et al., 2002). RGS2 binds either directly (M1 
muscarinic receptor, or a1A- and b2-adrenoceptors) or indirectly via interaction with a 
scaffold protein (a1B-adrenoceptor) to GPCRs. Through its unique G protein selectivity for 
G┙q/11, RGS2 appears to play a key role in cardiovascular pathophysiology, in which 
deleterious processes are often initiated via G┙q/11-coupled GPCRs; for example, in blood 
vessels, many contractile responses are mediated via G┙q (Wieland et al., 2007) . 
Activation of G┙q-mediated vasoconstrictor signaling pathways in vascular smooth muscle 
cells (VSMCs) mediates the action of several vasoconstrictor agonists, including 
noradrenaline, Ang II, vasopressin and endothelin. RGS2 is a selective and potent inhibitor 
of G┙q signalling that is ubiquitously expressed throughout the cardiovascular system. The 
biological significance of RGS2 in cardiovascular physiology is evident from blood pressure 
studies carried out in mice and humans. Several studies have shown that RGS2-null mice 
are hypertensive (Tang et al., 2003; Gross et al., 2005), with altered G-protein signaling in a 
number of tissues. These mice have agonist-dependent increases in G┙q signaling in VSMCs 
compared with wild-type controls. Moreover, RGS2-null mice also have increased pressor 
responses to infusion of Ang II and ┙-adrenergic receptor agonists compared with wild-type 
controls. This effect may be partly explained by increased myogenic vasoreactivity to G-
protein-mediated stimuli of the RGS2-null mice (Hercule et al., 2007). RGS2 has also been 
shown to be highly integrated within the NO mediated vasodilator pathway. Specifically, 
the N-terminal of RGS2 is phosphorylated by PKG (cGMP-dependent protein kinase), 
resulting in plasma membrane translocation and increased function as an inhibitor of 
vasoconstrictor signaling (Tang et al., 2003). Results from knockout animal studies also 
suggest that abnormal function of the autonomic nervous system contributes to the 
hypertensive phenotype, since they have increased urinary noradrenaline and altered 
baroreflex sensitivity. Moreover, through the ability of its N-terminal domain to directly 
inhibit specific adenylate cyclase isoforms (Gu et al., 2008b; Salim et al., 2003), RGS2 may 
attenuate signaling via receptors for dopamine and vasopressin in the kidney. Consistent 
with this suggestion, RGS2 was shown to regulate vasopressin responses in cortical 
collecting duct segments in vivo (Zuber et al., 2007). 
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4.3.2 RGS2 and Ang II action 
There is increasing evidence of a reciprocal association between RGS2 activity and Ang II 
signaling. RGS2 has been shown to modulate signaling through the AT1 receptor (Ang II 
type 1 receptor) in several reports mentioned above. However, it has also been shown that 
RGS2 mRNA expression is increased by Ang II signaling in several cell lines, suggesting that 
RGS2 is an important part of a negative-feedback loop for this pathway. Indeed, the Ang II-
stimulated expression of RGS2 has been shown to be able to inhibit both Ang II signaling (Li 
et al., 2005)  and aldosterone production (Romero et al., 2006) . Although the precise 
mechanism for the up regulation of Rgs2 is not fully understood, recent findings have 
implicated a role for PLA2 (phospholipase A2) in this process. Together, these results 
suggest a reciprocal relationship between RGS2 and Ang II, which is supported by in vivo 
studies showing that the Rgs2-null animals are more sensitive to Ang II-induced 
hypertension than wild-type controls (Hercule et al., 2007). 
4.3.3 Clinical hypertension and RGS2 deficiency 
The importance of RGS2 in the regulation of blood pressure homoeostasis is evident also in 
human studies. Recent studies have identified human genetic polymorphisms within the 
RGS2 locus that are associated with hypertension in different ethnic populations (Riddle et 
al., 2006; Freson et al., 2007). The RGS2 gene consists of five exons that show minimal 
genetic variation between subjects. No coding polymorphisms have been yet identified in 
Caucasian subjects; however, one single nucleotide polymorphism (SNP) was found in 
Black Americans (Riddle et al., 2006), and nine different SNPs in Japanese subjects (of which 
five are non-synonymous) (Yang et al., 2005). In the case of the Japanese population, 
hypomorphic RGS2 allele function could partially explain the development of hypertension 
in subjects carrying missense mutations at Q2L,Q2R and R44H. For example, Q2L and Q2R 
variant proteins were shown to be less stable compared with normal RGS2 and, as a result, 
these subjects are thought to express lower steady-state levels of RGS2. By contrast, another 
study showed that the R44H variant of RGS2, although not compromising stability, disrupt 
the amphipathic ┙-helix that is crucial for proper plasma-membrane targeting and function 
(Gu et al., 2008a). Notably, another mutation at the Arg44 position, R44G, has also been 
shown to be associated with hypertension and higher than normal BMI (body mass index), 
suggesting a further role of RGS2 in causing obesity and metabolic syndrome. In addition, to 
those changes identified in the coding regions, the promoter region, introns and 
untranslated regions of RGS2 also contain several SNPs and I/D (insertion/deletion) 
polymorphisms, of which one has been shown to result in enhanced calcium mobilization in 
fibroblasts in response to Ang II (Semplicini et al., 2006), and one has been linked to an 
increase in risk of the metabolic syndrome in white Caucasian Europeans (Freson et al., 
2007). Remarkably, their allelic frequency differs markedly between ethnicity, and some are 
exclusively found in one ethnic group. Taken together, these studies of both non-
synonymous mutations and extra-exonic polymorphisms suggest the possibility that RGS2 
variation contributes to some of the variability of blood pressure observed between different 
ethnic groups. 
Noteworthy, too much RGS2 may also provide a pathophysiological stimulus within the 
cardiovascular tissues. It has been reported that the RGS2 protein is overexpressed in 
patients with Bartter’s syndrome (B/S) and Gitelman’s syndromes (G/S), and that this 
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abnormally high expression inhibits Ang II-mediated intracellular calcium release (Calo’ et 
al., 1998) and promotes altered vascular remodeling. Indeed, fibroblasts taken from patients 
with B/S and G/S have enhanced RGS2 expression and reduced signaling through the AT1 
receptor (Calo’ et al., 2004), the effects of which can be normalized by the knockdown of 
RGS2 expression (Calo’ et al., 2008). 
All these findings strongly suggest that the precise control of RGS2 protein level and 
function is extremely important for the normal regulation of vascular function and blood 
pressure control. This hypothesis received further support by our findings that 1) RGS2 
expression is reduced in PBMs and in cultured fibroblasts from hypertensive patients in 
comparison with normotensive individuals (Semplicini et al., 2006), 2) low RGS2 expression 
predicts a poor response to antihypertensive treatment. In fact, resistant hypertensives were 
characterized by higher plasma aldosterone, ARR and reduced RGS2 expression in 
peripheral blood mononuclear cells in comparison to responder to antihypertensive drugs. 
(Semplicini et al., 2010). 
The association between resistant hypertension and low RGS2 expression suggests increased 
vascular tone of the resistance vessels due to unopposed Ang II-mediated vasoconstriction, 
while the association with high plasma aldosterone and high ARR is an indicator of 
disproportionate aldosterone response to Ang II in the adrenals.  
In the vasculature, chronic upregulation of Ang II activity, due to low RGS2 expression, was 
suggested not only by the finding of increased BP, but also of increased plasma BUN and 
urate levels, an indicator of increased renal efferent artery resistance, reduction of renal 
blood flow and increased hydraulic pressure in the glomerular capillary, with consequent 
increased glomerular filtration rate, and urate and sodium reabsorption along the early 
proximal tubule. (Perlstein et al., 2004; Johnson et al., 2005).  
In the adrenals, the association between low RGS2 and high plasma aldosterone and high 
ARR is an indicator of disproportionate aldosterone response to Ang II (Semplicini et al., 
2010). 
5. Disproportionate aldosterone secretion and reduced RGS2 expression:  
a proposed link in resistant hypertension deserving further investigations 
Identification and treatment of uncontrolled and resistant hypertension is a task of 
paramount importance in cardiovascular preventive medicine. In fact, poor blood pressure 
control carries unacceptably high risk of cardiovascular complications and premature death. 
Improving blood pressure control at individual and population level may reduce 
cardiovascular morbidity and mortality but this major goal can not be achieved with such a 
high prevalence of uncontrolled and resistant hypertension. 
The data summarized so far suggest which pathways should be investigated to unravel the 
pathophysiology of resistant hypertension and how to improve its drug treatment. The 
research results of our and others’ laboratories indicate that aldosterone plays a key role in 
the pathogenesis of resistant hypertension and suggest that aldosterone antagonists should 
be tested in selected patients with resistant hypertension. 
Calhoun et al. (2008) and Gallay et al. (2001) reported that PA is present in 20% of 
individuals with resistant hypertension. High-normal levels of circulating aldosterone 
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increase the risk of poor blood pressure control. High aldosterone with high ARR and low 
PRA may reflect either primary aldosterone overproduction or, more likely, increased 
adrenal response to Ang II.  
Our working hypothesis is that the exaggerated aldosterone production in resistant 
hypertensives is due to low RGS2 expression. This hypothesis originates from our recent 
findings (Semplicini et al., 2010) showing in a cohort of resistant hypertensives that: 
1. there is an inverse correlation between RGS2 expression and baseline BP,  
2. low RGS2 expression is associated with resistant hypertension,  
3. resistant hypertension with low RGS2 expression is associated with high plasma BUN 
and acid uric, indicating increased sodium and water reabsorption in the renal proximal 
tubules,  
4. resistant hypertension with low RGS2 is associated with high plasma aldosterone and 
ARR,  
5. the accuracy of RGS2 and ARR in predicting response to antihypertensive treatment is 
similar and not additive.  
Aldosterone stimulates RGS2 expression, and upregulation of RGS2 by Ang II functions as a 
negative feedback of aldosterone production. The fact that we showed in resistant 
hypertensives high aldosterone with low RGS2 expression provides strong support to our 
hypothesis that abnormal regulation of RGS2 expression increases the duration of action of 
the intracellular signaling cascade, leading to persistently increased secretion of aldosterone 
in resistant hypertensives. 
RGS2 is one of the genes involved in human essential hypertension, because it regulates the 
cell responses to Ang II and other vasoconstrictive agents and it controls peripheral 
vasoconstriction and blood pressure. Our data provide robust indication that reduced 
expression of RGS2 acts also as a promoter of aldosterone excess in resistant and 
uncontrolled hypertension. 
Dysregulation of RGS2 plays a crucial role in the pathogenesis of cardiovascular diseases, 
making RGS2 as a potential therapeutic target or biomarker of hypertension or hypertensive 
heart disease. There is no firm evidence of the cause of reduced RGS2 expression in resistant 
hypertension, but it could be associated to a susceptible genetic polymorphism, and it is still 
unknown how to control the activity of its gene to up-regulate its expression. 
On clinical grounds, according to our hypothesis, we propose a short course of aldosterone 
antagonists in resistant hypertensives. If it provides a good blood pressure response, long 
term treatment with aldosterone antagonists is recommended. This therapeutic approach 
has to be tested in long term controlled studies. In the meanwhile, further in depth studies 
of these mechanisms are recommended to allow a wider comprehension of resistant 
hypertension and to provide further support to its therapeutic approach with aldosterone 
antagonists. 
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